Cytokinetics (CYTK) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($0.60), $0.03 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $8.33 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Femasys Inc. (FEMY) Misses Q2 EPS by 20c
- Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
